One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
This press release contains forward-looking statements regarding
Genzyme's financial outlook and business plans and strategies, including
without limitation: its 2008 earnings guidance; its 2008 Myozyme revenue
guidance; its plans regarding the timing and content of the BLA submission
for Myozyme manufactured at the 2000L scale; it expectations regarding FDA
approval of that BLA and the timing thereof; its anticipated non-GAAP
compound growth rate through 2011; and its belief there is no difference in
the clinical effectiveness or safety of Myozyme produced at the 160L and
the 2000L scales. These statements are subject to risks and uncertainties
that could cause actual results to differ materially from those fore
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved